Aggressive Disease Treatment Patterns and CtDNA HRR evaluatiON in High-volume metastatiC hORmone-sensitive Prostate Cancer in Russian FeDeration

Male patients aged ≥ 18 years old;

Signed ICF, including consent for blood samples ctDNA and ctDNA-based HRRm testing;

Metastatic hormone-sensitive prostate cancer (mHSPC) (de novo or progressed from earlier stages);

High-aggressive disease (Gleason 8-10);